Pyxis Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Boston, June 28, 2024Pyxis Oncology, Inc. (Nasdaq: PYXS)
Pyxis Oncology, Inc. a clinical-stage biopharmaceutical company dedicated to developing next-generation therapeutics aimed at difficult-to-treat cancers, announced today that its Compensation Committee of the Board of Directors granted restricted stock units (RSUs) and stock options to five newly hired employees. The awards were made in compliance with Nasdaq Listing Rule 5635(c)(4) and are designed as an inducement material to new employees joining the company.
Inducement Grants Breakdown
On June 28, 2024, Pyxis Oncology’s Compensation Committee granted
- Restricted stock units (RSUs) for an aggregate total of 89,530 shares of Pyxis Oncology’s common stock.
- Stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology’s common stock.
These grants fall under the Pyxis Oncology, Inc. 2022 Inducement Plan, a strategic initiative aimed at attracting top talent essential for the advancement of Pyxis Oncology’s ambitious clinical and research programs.
Purpose of Inducement Grants
Inducement grants are a crucial tool for companies to attract and retain key employees by offering equity in the company. These grants serve as an added incentive, aligning the interests of the employees with those of the shareholders and providing motivation to achieve the long-term s of the company. By adhering to Nasdaq Listing Rule 5635(c)(4), Pyxis Oncology ensures that these equity awards are material and in compliance with proper governance protocols.
Nasdaq Listing Rule 5635(c)(4) permits listed companies to issue equity-based compensation outside of shareholder-approved compensation plans, provided such grants are a material inducement for new employment. This provision enables Pyxis Oncology to offer competitive compensation packages to new hires without the need for immediate shareholder approval, thus expediting the onboarding process for critical personnel.
Strategic Implications of New Hires
The addition of the five new employees is expected to bolster Pyxis Oncology’s clinical and operational capabilities as it continues to advance its pipeline of oncology therapeutics. These hires come at a pivotal time for the company, which is focused on developing innovative treatment options aimed at transforming the lives of patients affected by hard-to-treat cancers.
The Future of Pyxis Oncology
The strategic emphasis on cutting-edge research, coupled with a robust talent acquisition strategy, positions Pyxis Oncology to make significant strides in the oncology therapeutics space. The company’s commitment to bringing novel and effective treatments to patients is underscored by these recent hires and the associated inducement grants.
As Pyxis Oncology continues to grow and advance its clinical programs, the alignment of employee and shareholder interests through equity compensation remains a cornerstone of its growth strategy. These inducement grants are an important step in fostering a motivated workforce dedicated to achieving the company’s mission of targeting the most formidable challenges in cancer treatment.
About Pyxis Oncology
Founded on the principles of scientific innovation and patient-centric care, Pyxis Oncology is committed to delivering breakthrough treatments for cancers that are notoriously difficult to treat. The company leverages a deep understanding of cancer biology to develop new therapeutic modalities that offer hope to patients who have limited options.
With a focus on nurturing talent and driving scientific excellence, Pyxis Oncology aims to revolutionize cancer treatment and improve patient outcomes on a global scale.
Comments